Abstract
Introduction: Neoplasm metastasis is a multiple-step and multi-component involved pathogenesis causing large human mortality and socioeconomic burden. Currently, anti-metastatic drugs are the widest therapeutic targets for clinical cancer trials. The most effective drugs are yet to be developed. Methods: Anti-metastatic drugs are evaluated by a great variety of tumor models and cutting-edge biotechnology. Anti-metastatic drug evaluation and development is still a pharmaceutical challenge worldwide. Many technical deficit and knowledge limitation has been overcoming decade by decade. Discussion: Different aspects of chemical, pathologic, pharmacological and pharmaceutical knowledge breakthroughs for neoplasm metastasis evaluation are discussed. Better knowledge for the complexity of metastasis pathology is essential for therapeutic moving forward. Conclusion: A great therapeutic responses and benefits can be expected after aforementioned biomedical study, technical progression and drug development.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Hospice & Palliative Medicine International Journal
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
